Sept. 10, 2020: Concomitant use of vaginal rings with condoms; benefits of more frequent HIV screening for young MSM; Black MSM, substance use, and the PrEP continuum; HIV outcomes stratified by anti-LGTBQ policy across U.S. states.
A Vaginal Ring to Prevent HIV Was Given a Positive Opinion by a European Drug Regulator. Here’s What You Need to Know About It.
Two experts discuss the history of the ring, how it works, and when it may come to the United States.
July 30, 2020: HIV prevention shortfalls among adolescents of color; PrEP use among trans people; PrEP information gaps among women of color; the case for vacation-based (a.k.a. episodic) PrEP.
Richard Jefferys of Treatment Action Group discusses the pipeline for new modalities being explored for treatment, PrEP, vaccine, and cure.
July 16, 2020: Starting HIV treatment during hospitalization for people who use drugs; type of substance use affects viral suppression odds; benefits of a cross-disciplinary medical support team; does STI recency dictate PrEP necessity for women?
New data presented at AIDS 2020 show the long-acting injectable drug cabotegravir proved superior to daily oral TDF/FTC for MSM and transgender women.
This researcher has some ideas about what we need to do to address the problem.
Two researchers discuss their analysis of Philadelphia FIGHT’s HIV pre-exposure prophylaxis (PrEP) program for cisgender women.
Increased HIV Testing and Treatment for Black Bisexual Men May Have Played a Role in HIV Drop in Black Women. But Has the Stigma Gone Away?
Researchers say the “bisexual bridge” theory creates stigma and biphobia.
May 7, 2020: Epidemiological factors among transgender women; revised PrEP indication estimates for MSM; trends in HIV strain similarity between younger and older MSM; current hepatitis C epidemic among British MSM with HIV.